Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.
Jenburkt Pharmaceuticals financials and key ratios
Figures from the company's filings with NSE
In FY26 its consolidated net profit was ₹34.7 crore on revenue of ₹169 crore.
Jenburkt Pharmaceuticals at a glance · consolidated
Free cash flow (FY26)
₹26.5 Cr−5.0% vs FY25
Questions
What is the Jenburkt Pharmaceuticals dividend in 2026 and its record date?
In 2026, Jenburkt Pharmaceuticals has declared one dividend: ₹20.70 with record date 28 August 2026.
What is the Jenburkt Pharmaceuticals free cash flow?
In FY26, Jenburkt Pharmaceuticals generated ₹26.5 crore of cash from operations and spent ₹0 lakh on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹26.5 crore. In FY25 it was ₹27.9 crore.
What is the Jenburkt Pharmaceuticals revenue and profit in FY26?
In FY26 (April 2025–March 2026), Jenburkt Pharmaceuticals' consolidated net profit was ₹34.7 crore, up 8.3% from ₹32.1 crore in FY25, on revenue from operations of ₹169 crore (up 11.2%). Over three years, from FY23, net profit was up 41.2%.
How does Jenburkt Pharmaceuticals compare with its peers?
On FY26 consolidated figures, against Makers Laboratories: Jenburkt Pharmaceuticals' operating margin of 23.8% is the higher of the two (Makers Laboratories −4.1%; peer average −4.1%); its revenue growth over three years of 7.3% a year is the higher of the two (Makers Laboratories 5.8% a year; peer average 5.8% a year).
Jenburkt Pharmaceuticals vs Makers Laboratories: how do they compare?
In FY26, Jenburkt Pharmaceuticals earned net profit of ₹34.7 crore on revenue of ₹169 crore, against ₹1.7 crore on ₹50.3 crore for Makers Laboratories. Jenburkt Pharmaceuticals' operating margin was 23.8% (Makers Laboratories −4.1%).
Where do these Jenburkt Pharmaceuticals figures come from?
From Jenburkt Pharmaceuticals' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
